Healthy
Conditions
Keywords
Absolute bioavailability, Pharmacokinetics
Brief summary
A Phase 1 study to assess the bioavailability and pharmacokinetics of a 600 mg immediate release tablet formulation of lefamulin when administered to fed and fasted healthy subjects in comparison to an intravenous formulation and a capsule formulation.
Detailed description
This is a single center, single cohort, open label, randomized, four- period cross-over study with healthy subjects receiving a single dose of lefamulin at four study sessions at least 4 days apart. Lefamulin will be taken: 1) as 600 mg IR tablet orally in the fasted state; 2) as 600 mg API in capsule (3 x 200 mg capsules) orally in the fasted state; 3) as 150 mg i.v. infusion in 250 mL citrate buffered saline over 1 h; 4) as 600 mg IR tablet orally one hour after breakfast. The order will be randomized. A total of 20 healthy subjects will be enrolled in the study. The same subjects will take part in all study sessions. After each study session, the Safety Monitoring Team will review the safety and tolerance data before the commencement of the subsequent session.
Interventions
DRUGLefamulin
Lefamulin administered iv or orally in the fasted state and orally in the fed state
Sponsors
Nabriva Therapeutics AG
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy subjects 18-55 years of age * Good state of health (mentally and physically) as determined by the investigator * Body mass index within the range 19 to 32 kg/m2 inclusive * A signed and dated written informed consent form * The subject is able to understand and willing to comply with protocol requirements and timetables, instructions and protocol-stated restrictions
Exclusion criteria
* Any acute or chronic illness or clinically relevant abnormality identified on the screening medical assessment, laboratory tests or ECG (12-lead or Holter), unless in the opinion of the investigator, in consultation with the Nabriva medical monitor, it will not interfere with the study procedures, affect the outcome of the study or compromise the safety of the subject * A known history of chronic liver or biliary disease, history of Gilbert's syndrome or an elevated bilirubin level * History of gastritis, gastrointestinal tract disorders or other clinical condition or previous surgery that might affect the absorption, distribution, biotransformation, or excretion of lefamulin * Use of prescription or non-prescription drugs within 7 days or 10 times the elimination half-life (whichever is longer) prior to first dose of study medication * Any intake of prescription or non-prescription drugs known to induce or inhibit drug-metabolizing enzymes or transport system enzymes within a period of less than 10 times the respective elimination half-life, or intake of grapefruit juice or grapefruit containing products within 7 days prior to first dose of study drug.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The area under the concentration time curve (AUC) of an intravenous and oral formulation of lefamulin in the fasting state | 36 hours |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The area under the concentration time curve (AUC) of a tablet and capsule formulation of lefamulin in the fasting state | 36 hours | — |
| The area under the concentration time curve (AUC) of a 600 mg IR tablet of lefamulin in the fed state | 36 hours | — |
| Assessment of the safety and tolerability of lefamulin when administered, as single doses orally and i.v. to healthy subjects aged 18 to 55 years (adverse events, laboratory assessments, vital signs and electrocardiograms) | 36 hours | Assessment of safety and tolerability by recording adverse events, laboratory assessments, vital signs and electrocardiograms |
Countries
United Kingdom
Outcome results
None listed